11/19
03:03 pm
enta
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development [Seeking Alpha]
Low
Report
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development [Seeking Alpha]
11/17
04:45 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 [Yahoo! Finance]
11/17
04:12 pm
enta
Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M [Seeking Alpha]
Medium
Report
Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M [Seeking Alpha]
11/17
04:01 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
11/14
08:09 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
11/4
07:00 am
enta
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
10/24
12:22 pm
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/20
07:00 am
enta
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Low
Report
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
10/7
07:33 am
enta
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 [Yahoo! Finance]
10/7
07:00 am
enta
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Low
Report
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
10/2
04:01 pm
enta
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
10/1
11:15 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.
Medium
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.
10/1
11:15 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.
Medium
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.
9/30
09:00 pm
enta
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Medium
Report
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
9/30
05:16 pm
enta
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
9/30
04:11 pm
enta
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
Medium
Report
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
9/30
08:05 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target raised by analysts at Westpark Capital from $24.00 to $28.00. They now have a "buy" rating on the stock.
High
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target raised by analysts at Westpark Capital from $24.00 to $28.00. They now have a "buy" rating on the stock.
9/29
01:45 pm
enta
Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults [Yahoo! Finance]
High
Report
Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults [Yahoo! Finance]
9/29
06:44 am
enta
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults [Yahoo! Finance]
High
Report
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults [Yahoo! Finance]
9/29
06:30 am
enta
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
High
Report
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
9/26
04:20 pm
enta
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults [Yahoo! Finance]
High
Report
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults [Yahoo! Finance]
9/26
04:01 pm
enta
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
High
Report
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
9/15
10:16 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target lowered by analysts at Evercore ISI from $20.00 to $12.00. They now have an "outperform" rating on the stock.
Medium
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target lowered by analysts at Evercore ISI from $20.00 to $12.00. They now have an "outperform" rating on the stock.